Summary
Project summary: Current treatment for Glioblastoma Multiforme (GBM), the most common malignant brain tumor in adults, involves maximal safe resection, followed by adjuvant chemoradiation. Although this treatment is life prolonging, it is never curative. Five year survival is less than 7 %1 and improved therapies are urgently needed. In this proposal, we aim to develop a new targeted therapy with reduced toxicity and increased efficacy for GBM patients by leveraging nanotechnology discoveries in our laboratory to improve adoptive cell therapy. Chimeric Antigen Receptor (CAR) T cells combine th
